Defense Health Agency Issues New Authority to GlobalMed

Authority to Operate enables all Defense Health Agency locations to purchase and utilize GlobalMed's Virtual Health Technologies

GlobalMed, an international provider of telehealth solutions, today announced that its industry leading virtual health platform has earned the Defense Health Agency (DHA) Authority to Operate (ATO) on the U.S. Department of Defense (DoD) DHA Medical Community of Interest (Med COI) network.

GlobalMed’s virtual health solutions are the first synchronous clinical virtual health technologies awarded an ATO. This much coveted certification enables GlobalMed to integrate their virtual health platform including carts, medical devices, software, and applications directly with the DHA’s Med COI network, making their solutions available to integrate with MHS Genesis, the new patient-centric enterprise system designed to provide a single, continuous record of care for all DOD beneficiaries. In addition to providing medical care on the battlefield and at bases overseas (as well as on ships) DHA’s network includes 721 military treatment facilities and 174,000 health care personnel, which provide health services to approximately 9.6 million beneficiaries.

“It has always been a personal priority to increase health care access for the members and families of the Army, Navy, Air Force, Marines, Space Force and Coast Guard,” said Joel E. Barthelemy, CEO and Vice Chairman of GlobalMed and a Marine Corps Reserve Veteran. “The Department of Defense is a huge healthcare provider and network security is a high priority. GlobalMed is committed to every aspect of security and compliance throughout our applications having recently completed our SOC 2 Type 2 examination with even more stringent security attestations on our road map. Our commitment to delivering unmatched performance, security and scalability extends beyond our government clients to those in the commercial enterprise space, giving physician groups and non-government hospitals an added measure of reassurance.”

DHA selected GlobalMed for its HIPAA-compliant virtual telemedicine platform that seamlessly and securely connects healthcare professionals and patients, regardless of location. GlobalMed is also the telehealth provider for the White House Medical Unit and has deployed their solutions across the VA hospitals and extension centers, and other U.S. Departments and Agencies.

SourceGlobalMed

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version